NW
← Newsroom
Quantum TechNovember 12, 2026 · 2 min read

PsiQuantum and AMD expand partnership on quantum computing infrastructure

Palo Alto, 12 November 2026. PsiQuantum and AMD announced an expanded strategic partnership to co-design the computing infrastructure required to operate utility-scale, fault-tolerant quantum computers and the hybrid applications that combine quantum, high-performance and AI computing. The companies said the work builds on existing collaboration around AMD Versal FPGA technology, which PsiQuantum selected for development of its fault-tolerant quantum computing platform.

The expanded relationship spans AMD Instinct GPUs, AMD EPYC CPUs and the AMD ROCm software stack, combined with PsiQuantum's silicon photonics platform and its fully integrated platform. AMD also plans to make an equity investment into PsiQuantum to reinforce its commitment to the partnership. The companies expect the integration of classical high-performance, AI and photonic quantum computing technology to form a hybrid computing fabric.

"Quantum computing will enable solving problems in healthcare, materials, energy, finance, and other domains that are out of reach today, working in concert with AI and high-performance computing," said Victor Peng, Chief Executive Officer of PsiQuantum. Mark Papermaster, Executive Vice President, Chief Technology Officer, AMD, said: "We see that same opportunity with quantum computing, where leadership in classical computing is essential to building systems at scale."

The collaboration aligns with the U.S. Department of Energy's recently released Quantum Genesis Priority Applications. PsiQuantum said its computational chemistry methodologies are performing beyond state-of-the-art calculations on AMD hardware today, and the planned initial focus on drug discovery falls within biological modeling, an identified emerging application area for Quantum Genesis.

PsiQuantum researchers have optimized a machine-learning decoder called PRISM for low-latency implementation on programmable hardware accelerators, aimed at real-time error correction in utility-scale photonic quantum computers. The combination of PsiQuantum's workflows with AMD's GPU expertise in large scale simulation has delivered initial results in simulation of covalent inhibitors, a class of molecules relevant in drug discovery for oncology. PsiQuantum plans to explore integrated accelerated computing solutions for commercial applications, initially focusing on pharmaceutical research and drug discovery.

Both companies will also explore expanding their collaboration with a footprint at the Illinois Quantum and Microelectronics Park (IQMP) in Chicago, where PsiQuantum serves as anchor tenant. AMD and PsiQuantum will share more about the partnership at SC26 (November 15-20) in Chicago.

Source: PsiQuantum news